Latin America, Middle East & Africa Pharmacogenomics Market (2019-2025)
The Latin America, Middle East and Africa Pharmacogenomics Market would witness market growth of 9.9% CAGR during the forecast period (2019–2025).
Chronic diseases are spreading at an alarming rate which has consequently boosted the demand for precision and personalized medicine. Pharmacogenomics has been widely recognized as a fundamental step in personalized medicine and growing demand for personalized medicine is propelling the growth of the global pharmacogenomics market.
Pharmacogenomics is expected to facilitate the treatment of a wide spectrum of diseases such as cardiovascular diseases, Alzheimer disease, HIV/AIDS, and cancer among others. An upsurge in the investments for technology advancements is primarily poised to revolutionize the pharmacogenomics market. Furthermore, it also supports the customization of medicine doses according to a person’s genetics.
Based on Technology, the market is segmented into Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others. Based on Application, the market is segmented into Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others. Based on End User, the market is segmented into Hospitals and Clinics, Research Institutions, and Academic Institutes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
Scope of the Study
Market Segmentation:
By Application
Chronic diseases are spreading at an alarming rate which has consequently boosted the demand for precision and personalized medicine. Pharmacogenomics has been widely recognized as a fundamental step in personalized medicine and growing demand for personalized medicine is propelling the growth of the global pharmacogenomics market.
Pharmacogenomics is expected to facilitate the treatment of a wide spectrum of diseases such as cardiovascular diseases, Alzheimer disease, HIV/AIDS, and cancer among others. An upsurge in the investments for technology advancements is primarily poised to revolutionize the pharmacogenomics market. Furthermore, it also supports the customization of medicine doses according to a person’s genetics.
Based on Technology, the market is segmented into Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others. Based on Application, the market is segmented into Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others. Based on End User, the market is segmented into Hospitals and Clinics, Research Institutions, and Academic Institutes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
Scope of the Study
Market Segmentation:
By Application
- Sequencing
- Polymerase Chain Reaction
- Electrophoresis
- Mass Spectrometry
- Microarray
- Others
- Oncology
- Psychiatry
- Infectious Diseases
- Neurological Diseases
- Pain management
- Cardiovascular Diseases
- Others
- Hospitals and Clinics
- Research Institutions
- Academic Institutes
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
- Abbott Laboratories
- Empire Genomics LLC
- Illumina, Inc.
- Oneome LLC
- Myriad Genetics Inc.
- Thermo Fisher Scientific, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bayer AG
- Opko Health, Inc.
- Becton, Dickinson and Company
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Pharmacogenomics Market, by Application
1.4.2 LAMEA Pharmacogenomics Market, by Application
1.4.3 LAMEA Pharmacogenomics Market, by End User
1.4.4 LAMEA Pharmacogenomics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY
3.1.1 LAMEA Sequencing Market by Country
3.1.2 LAMEA Polymerase Chain Reaction Market by Country
3.1.3 LAMEA Electrophoresis Market by Country
3.1.4 LAMEA Mass Spectrometry Market by Country
3.1.5 LAMEA Microarray Market by Country
3.1.6 LAMEA Others Market by Country
CHAPTER 4. LAMEA PHARMACOGENOMICS MARKET BY APPLICATION
4.1.1 LAMEA Oncology Market by Country
4.1.2 LAMEA Psychiatry Market by Country
4.1.3 LAMEA Infectious Diseases Market by Country
4.1.4 LAMEA Neurological Diseases Market by Country
4.1.5 LAMEA Pain Management Market by Country
4.1.6 LAMEA Cardiovascular Diseases Market by Country
4.1.7 LAMEA Others Market by Country
CHAPTER 5. LAMEA PHARMACOGENOMICS MARKET BY END USER
5.1.1 LAMEA Hospitals and Clinics Market by Country
5.1.2 LAMEA Research Institutions Market by Country
5.1.3 LAMEA Academic Institutes Market by Country
CHAPTER 6. LAMEA PHARMACOGENOMICS MARKET BY COUNTRY
6.1 Brazil Pharmacogenomics Market
6.1.1 Brazil Pharmacogenomics Market by Technology
6.1.2 Brazil Pharmacogenomics Market by Application
6.1.3 Brazil Pharmacogenomics Market by End User
6.2 Argentina Pharmacogenomics Market
6.2.1 Argentina Pharmacogenomics Market by Technology
6.2.2 Argentina Pharmacogenomics Market by Application
6.2.3 Argentina Pharmacogenomics Market by End User
6.3 UAE Pharmacogenomics Market
6.3.1 UAE Pharmacogenomics Market by Technology
6.3.2 UAE Pharmacogenomics Market by Application
6.3.3 UAE Pharmacogenomics Market by End User
6.4 Saudi Arabia Pharmacogenomics Market
6.4.1 Saudi Arabia Pharmacogenomics Market by Technology
6.4.2 Saudi Arabia Pharmacogenomics Market by Application
6.4.3 Saudi Arabia Pharmacogenomics Market by End User
6.5 South Africa Pharmacogenomics Market
6.5.1 South Africa Pharmacogenomics Market by Technology
6.5.2 South Africa Pharmacogenomics Market by Application
6.5.3 South Africa Pharmacogenomics Market by End User
6.6 Nigeria Pharmacogenomics Market
6.6.1 Nigeria Pharmacogenomics Market by Technology
6.6.2 Nigeria Pharmacogenomics Market by Application
6.6.3 Nigeria Pharmacogenomics Market by End User
6.7 Rest of LAMEA Pharmacogenomics Market
6.7.1 Rest of LAMEA Pharmacogenomics Market by Technology
6.7.2 Rest of LAMEA Pharmacogenomics Market by Application
6.7.3 Rest of LAMEA Pharmacogenomics Market by End User
CHAPTER 7. COMPANY PROFILES
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Collaborations, partnerships and agreements:
7.1.5.2 Product launches:
7.1.5.3 Acquisition and mergers:
7.1.6 SWOT Analysis
7.2 Empire Genomics LLC
7.2.1 Company Overview
7.3 Illumina, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional& Segmental Analysis
7.3.4 Research& Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Collaborations, partnerships and agreements:
7.3.5.2 Product launches:
7.3.5.3 Acquisition and mergers:
7.4 OneOme LLC
7.4.1 Company Overview
7.5 Myriad Genetics Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Product launches:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.6.6 SWOT Analysis
7.7 Teva Pharmaceuticals Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.8 Bayer AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.8.6 SWOT Analysis
7.9 Opko Health, Inc. (GeneDx, Inc.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expense
7.9.4 Recent strategies and developments:
7.9.4.1 Collaborations, partnerships and agreements:
7.9.4.2 Product launches:
7.1 Becton, Dickinson and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Collaborations, partnerships and agreements:
7.10.5.2 Acquisition and mergers:
7.10.5.3 Product launches:
7.10.6 SWOT Analysis
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Pharmacogenomics Market, by Application
1.4.2 LAMEA Pharmacogenomics Market, by Application
1.4.3 LAMEA Pharmacogenomics Market, by End User
1.4.4 LAMEA Pharmacogenomics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY
3.1.1 LAMEA Sequencing Market by Country
3.1.2 LAMEA Polymerase Chain Reaction Market by Country
3.1.3 LAMEA Electrophoresis Market by Country
3.1.4 LAMEA Mass Spectrometry Market by Country
3.1.5 LAMEA Microarray Market by Country
3.1.6 LAMEA Others Market by Country
CHAPTER 4. LAMEA PHARMACOGENOMICS MARKET BY APPLICATION
4.1.1 LAMEA Oncology Market by Country
4.1.2 LAMEA Psychiatry Market by Country
4.1.3 LAMEA Infectious Diseases Market by Country
4.1.4 LAMEA Neurological Diseases Market by Country
4.1.5 LAMEA Pain Management Market by Country
4.1.6 LAMEA Cardiovascular Diseases Market by Country
4.1.7 LAMEA Others Market by Country
CHAPTER 5. LAMEA PHARMACOGENOMICS MARKET BY END USER
5.1.1 LAMEA Hospitals and Clinics Market by Country
5.1.2 LAMEA Research Institutions Market by Country
5.1.3 LAMEA Academic Institutes Market by Country
CHAPTER 6. LAMEA PHARMACOGENOMICS MARKET BY COUNTRY
6.1 Brazil Pharmacogenomics Market
6.1.1 Brazil Pharmacogenomics Market by Technology
6.1.2 Brazil Pharmacogenomics Market by Application
6.1.3 Brazil Pharmacogenomics Market by End User
6.2 Argentina Pharmacogenomics Market
6.2.1 Argentina Pharmacogenomics Market by Technology
6.2.2 Argentina Pharmacogenomics Market by Application
6.2.3 Argentina Pharmacogenomics Market by End User
6.3 UAE Pharmacogenomics Market
6.3.1 UAE Pharmacogenomics Market by Technology
6.3.2 UAE Pharmacogenomics Market by Application
6.3.3 UAE Pharmacogenomics Market by End User
6.4 Saudi Arabia Pharmacogenomics Market
6.4.1 Saudi Arabia Pharmacogenomics Market by Technology
6.4.2 Saudi Arabia Pharmacogenomics Market by Application
6.4.3 Saudi Arabia Pharmacogenomics Market by End User
6.5 South Africa Pharmacogenomics Market
6.5.1 South Africa Pharmacogenomics Market by Technology
6.5.2 South Africa Pharmacogenomics Market by Application
6.5.3 South Africa Pharmacogenomics Market by End User
6.6 Nigeria Pharmacogenomics Market
6.6.1 Nigeria Pharmacogenomics Market by Technology
6.6.2 Nigeria Pharmacogenomics Market by Application
6.6.3 Nigeria Pharmacogenomics Market by End User
6.7 Rest of LAMEA Pharmacogenomics Market
6.7.1 Rest of LAMEA Pharmacogenomics Market by Technology
6.7.2 Rest of LAMEA Pharmacogenomics Market by Application
6.7.3 Rest of LAMEA Pharmacogenomics Market by End User
CHAPTER 7. COMPANY PROFILES
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Collaborations, partnerships and agreements:
7.1.5.2 Product launches:
7.1.5.3 Acquisition and mergers:
7.1.6 SWOT Analysis
7.2 Empire Genomics LLC
7.2.1 Company Overview
7.3 Illumina, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional& Segmental Analysis
7.3.4 Research& Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Collaborations, partnerships and agreements:
7.3.5.2 Product launches:
7.3.5.3 Acquisition and mergers:
7.4 OneOme LLC
7.4.1 Company Overview
7.5 Myriad Genetics Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Product launches:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.6.6 SWOT Analysis
7.7 Teva Pharmaceuticals Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.8 Bayer AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.8.6 SWOT Analysis
7.9 Opko Health, Inc. (GeneDx, Inc.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expense
7.9.4 Recent strategies and developments:
7.9.4.1 Collaborations, partnerships and agreements:
7.9.4.2 Product launches:
7.1 Becton, Dickinson and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Collaborations, partnerships and agreements:
7.10.5.2 Acquisition and mergers:
7.10.5.3 Product launches:
7.10.6 SWOT Analysis
LIST OF TABLES
TABLE 1 LAMEA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 LAMEA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 4 LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 5 LAMEA SEQUENCING MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 LAMEA SEQUENCING MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 LAMEA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 LAMEA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 LAMEA ELECTROPHORESIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 LAMEA ELECTROPHORESIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 LAMEA MASS SPECTROMETRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 LAMEA MASS SPECTROMETRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 LAMEA MICROARRAY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 LAMEA MICROARRAY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 LAMEA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 16 LAMEA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 17 LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 18 LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 19 LAMEA ONCOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 LAMEA ONCOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 LAMEA PSYCHIATRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 LAMEA PSYCHIATRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 LAMEA INFECTIOUS DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 LAMEA INFECTIOUS DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 LAMEA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 LAMEA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 LAMEA PAIN MANAGEMENT MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 28 LAMEA PAIN MANAGEMENT MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 29 LAMEA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 LAMEA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 LAMEA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 LAMEA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 LAMEA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 34 LAMEA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 35 LAMEA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 LAMEA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 LAMEA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 38 LAMEA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 LAMEA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 LAMEA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 LAMEA PHARMACOGENOMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 42 LAMEA PHARMACOGENOMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 43 BRAZIL PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 44 BRAZIL PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 45 BRAZIL PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 46 BRAZIL PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 47 BRAZIL PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 48 BRAZIL PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 49 BRAZIL PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 50 BRAZIL PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 51 ARGENTINA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 52 ARGENTINA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 53 ARGENTINA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 54 ARGENTINA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 55 ARGENTINA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 ARGENTINA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 ARGENTINA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 58 ARGENTINA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 59 UAE PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 60 UAE PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 61 UAE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 62 UAE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 63 UAE PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 64 UAE PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 65 UAE PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 66 UAE PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 67 SAUDI ARABIA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 68 SAUDI ARABIA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 69 SAUDI ARABIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 70 SAUDI ARABIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 71 SAUDI ARABIA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 72 SAUDI ARABIA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 73 SAUDI ARABIA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 74 SAUDI ARABIA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 75 SOUTH AFRICA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 76 SOUTH AFRICA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 77 SOUTH AFRICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 78 SOUTH AFRICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 79 SOUTH AFRICA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 80 SOUTH AFRICA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 81 SOUTH AFRICA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 82 SOUTH AFRICA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 83 NIGERIA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 84 NIGERIA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 85 NIGERIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 86 NIGERIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 87 NIGERIA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 88 NIGERIA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 89 NIGERIA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 90 NIGERIA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 91 REST OF LAMEA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 92 REST OF LAMEA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 93 REST OF LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 94 REST OF LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 95 REST OF LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 96 REST OF LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 97 REST OF LAMEA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 98 REST OF LAMEA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 99 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 100 KEY INFORMATION - EMPIRE GENOMICS LLC
TABLE 101 KEY INFORMATION – ILLUMINA, INC.
TABLE 102 KEY INFORMATION – ONEOME LLC
TABLE 103 KEY INFORMATION – MYRIAD GENETICS INC.
TABLE 104 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC.
TABLE 105 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 106 KEY INFORMATION – BAYER AG
TABLE 107 KEY INFORMATION – OPKO HEALTH, INC.
TABLE 108 KEY INFORMATION – BECTON, DICKINSON AND COMPANY
TABLE 1 LAMEA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 LAMEA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 4 LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 5 LAMEA SEQUENCING MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 LAMEA SEQUENCING MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 LAMEA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 LAMEA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 LAMEA ELECTROPHORESIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 LAMEA ELECTROPHORESIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 LAMEA MASS SPECTROMETRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 LAMEA MASS SPECTROMETRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 LAMEA MICROARRAY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 LAMEA MICROARRAY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 LAMEA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 16 LAMEA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 17 LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 18 LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 19 LAMEA ONCOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 LAMEA ONCOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 LAMEA PSYCHIATRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 LAMEA PSYCHIATRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 LAMEA INFECTIOUS DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 LAMEA INFECTIOUS DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 LAMEA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 LAMEA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 LAMEA PAIN MANAGEMENT MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 28 LAMEA PAIN MANAGEMENT MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 29 LAMEA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 LAMEA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 LAMEA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 LAMEA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 LAMEA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 34 LAMEA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 35 LAMEA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 LAMEA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 LAMEA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 38 LAMEA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 LAMEA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 LAMEA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 LAMEA PHARMACOGENOMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 42 LAMEA PHARMACOGENOMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 43 BRAZIL PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 44 BRAZIL PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 45 BRAZIL PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 46 BRAZIL PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 47 BRAZIL PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 48 BRAZIL PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 49 BRAZIL PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 50 BRAZIL PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 51 ARGENTINA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 52 ARGENTINA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 53 ARGENTINA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 54 ARGENTINA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 55 ARGENTINA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 ARGENTINA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 ARGENTINA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 58 ARGENTINA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 59 UAE PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 60 UAE PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 61 UAE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 62 UAE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 63 UAE PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 64 UAE PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 65 UAE PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 66 UAE PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 67 SAUDI ARABIA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 68 SAUDI ARABIA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 69 SAUDI ARABIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 70 SAUDI ARABIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 71 SAUDI ARABIA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 72 SAUDI ARABIA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 73 SAUDI ARABIA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 74 SAUDI ARABIA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 75 SOUTH AFRICA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 76 SOUTH AFRICA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 77 SOUTH AFRICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 78 SOUTH AFRICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 79 SOUTH AFRICA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 80 SOUTH AFRICA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 81 SOUTH AFRICA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 82 SOUTH AFRICA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 83 NIGERIA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 84 NIGERIA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 85 NIGERIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 86 NIGERIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 87 NIGERIA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 88 NIGERIA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 89 NIGERIA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 90 NIGERIA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 91 REST OF LAMEA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 92 REST OF LAMEA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 93 REST OF LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 94 REST OF LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 95 REST OF LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 96 REST OF LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 97 REST OF LAMEA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 98 REST OF LAMEA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 99 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 100 KEY INFORMATION - EMPIRE GENOMICS LLC
TABLE 101 KEY INFORMATION – ILLUMINA, INC.
TABLE 102 KEY INFORMATION – ONEOME LLC
TABLE 103 KEY INFORMATION – MYRIAD GENETICS INC.
TABLE 104 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC.
TABLE 105 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 106 KEY INFORMATION – BAYER AG
TABLE 107 KEY INFORMATION – OPKO HEALTH, INC.
TABLE 108 KEY INFORMATION – BECTON, DICKINSON AND COMPANY
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 2 SWOT ANALYSIS: ABBOTT LABORATORIES
FIG 3 SWOT ANALYSIS: THERMO FISHER SCIENTIFIC, INC.
FIG 4 SWOT ANALYSIS: BAYER AG
FIG 5 SWOT ANALYSIS: BECTON, DICKINSON AND COMPANY
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 2 SWOT ANALYSIS: ABBOTT LABORATORIES
FIG 3 SWOT ANALYSIS: THERMO FISHER SCIENTIFIC, INC.
FIG 4 SWOT ANALYSIS: BAYER AG
FIG 5 SWOT ANALYSIS: BECTON, DICKINSON AND COMPANY
